@article{3082393,
    title = "The prognostic significance of CA 125 in patients with non-Hodgkin's
lymphoma",
    author = "Zacharos, ID and Efstathiou, SP and Petreli, E and Georgiou, G and and Tsioulos, DI and Mastorantonakis, SE and Christakopoulou, I and Roussou, and PP",
    journal = "European Journal of Haematology",
    year = "2002",
    volume = "69",
    number = "4",
    pages = "221-226",
    publisher = "Blackwell Munksgaard",
    issn = "0902-4441, 1600-0609",
    doi = "10.1034/j.1600-0609.2002.02771.x",
    keywords = "tumor marker; CA 125; non-Hodgkin’s lymphoma; prognosis; survival",
    abstract = "Objective: To assess the association of serum CA 125 in patients with
non-Hodgkin’s lymphoma (NHL) with prognostic parameters of the disease,
response to treatment, and survival. Patients and methods: Sixty-eight
patients [38 males, median age 56 (range 17-82) yr] with NHL were
evaluated. CA 125 was measured by an enzyme immunoradiometric assay at
diagnosis and at the end of firstline treatment. Results: Median overall
CA 125 was 49 (1-963) U mL(-1), whereas 49 patients had initially
abnormal (> 35 U mL) CA 125 levels. High CA 125 was found to correlate
with failure of treatment (P = 0.001) and relapse (P = 0.01), and to be
independently associated with bulky disease, effusions, LDH, and the
International Prognostic Index (IPI) score (P < 0.01 for each of these
four variables). An initially abnormal CA 125 value was associated with
poorer 5-yr survival [median survival of patients with CA 125> 35 U
mL(-1) 33 (18-72) months compared to 58 (20-77) months for those with CA
125 = 35 U mL(-1), P = 0.012]. Moreover, CA 125> 35 U mL(-1) (among
stage III/IV and LDH> 460 mU mL(-1)) emerged as an independent predictor
of death within 5 yr from diagnosis (Relative Risk (RR) 3.1, 95% CI
1.5-12.8, P = 0.02). Conclusion: Measurement of serum CA 125 is useful
for staging, monitoring, and estimating prognosis in patients with NHL."
}